OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 22:59 UTC. Every row links to its source record.

SRSF2 serine and arginine rich splicing factor 2

ENSG00000161547 · protein coding · Open Targets profile

Necessary for the splicing of pre-mRNA. It is required for formation of the earliest ATP-dependent splicing complex and interacts with spliceosomal components bound to both the 5'- and 3'-splice sites during spliceosome assembly. It also is required for ATP-dependent interactions of both U1 and U2 snRNPs with pre-mRNA. Interacts with other spliceosomal components, via the RS domains, to form a bridge between the 5'- and 3'-splice site binding components, U1 snRNP and U2AF. Binds to purine-rich RNA sequences, either 5'-AGSAGAGTA-3' (S=C or G) or 5'-GTTCGAGTA-3'. Can bind to beta-globin mRNA and commit it to the splicing pathway. The phosphorylated form (by SRPK2) is required for cellular apoptosis in response to cisplatin treatment. .

In 14 of 15 cancers, the evidence for SRSF2 comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751acute myeloid leukemiaacute myeloid leukemiaacute myeloid leukemia: somatic 0.60acute myeloid leukemia: germline 0.93myelodysplastic syndromemyelodysplastic syndromemyelodysplastic syndrome: somatic 0.61myelodysplastic syndrome: germline 0.95chronic myelomonocytic leukemiachronic myelomonocytic leukemiachronic myelomonocytic leukemia: somatic 0.61chronic myelomonocytic leukemia: germline 0.87lymphoid neoplasmlymphoid neoplasmlymphoid neoplasm: somatic 0.46lymphoid neoplasm: germline 0.90myeloproliferative disordermyeloproliferative disordermyeloproliferative disorder: somatic 0.46myeloproliferative disorder: germline 0.84myeloid leukemiamyeloid leukemiamyeloid leukemia: germline 0.96hematopoietic and lymphoid system neopl…hematopoietic and lymphoid system neoplasmhematopoietic and lymphoid system neoplasm: germline 0.94monocytic leukemiamonocytic leukemiamonocytic leukemia: germline 0.93myeloid neoplasmmyeloid neoplasmmyeloid neoplasm: somatic 0.61myeloid neoplasm: germline 0.76Common Hematopoietic NeoplasmCommon Hematopoietic NeoplasmCommon Hematopoietic Neoplasm: germline 0.90hematopoietic and lymphoid cell neoplasmhematopoietic and lymphoid cell neoplasmhematopoietic and lymphoid cell neoplasm: germline 0.76adult acute myeloid leukemiaadult acute myeloid leukemiaadult acute myeloid leukemia: germline 0.76chronic myeloid leukemiachronic myeloid leukemiachronic myeloid leukemia: somatic 0.61chronic myeloid leukemia: germline 0.60leukemialeukemialeukemia: germline 0.65primary myelofibrosisprimary myelofibrosisprimary myelofibrosis: germline 0.66

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
Database Ubiquitination, Half-life Data

gnomAD loss of function constraint: o/e 0.25508999824523926 (upper bound 0.5837399959564209). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of SRSF2's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of SRSF2's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.